An emerging body of research highlights plant-based vaccine manufacturing as a potential solution to risks posed by traditional egg-based manufacturing.
A phase 2 study assessed safety and immunogenicity of administering a high-dose quadrivalent influenza vaccine with a mRNA-1273 vaccine booster dose in older adults.
Researchers evaluated the risk of confounding bias in simulated test-negative studies that assessed estimated COVID-19 and influenza vaccine effectiveness.
Researchers conducted a study that compared early treatment with inhaled zanamivir vs oral oseltamivir on the risk for hospitalization or death due to influenza infection.
For children aged 5 to 17 years with asthma, quadrivalent live attenuated influenza vaccine (LAIV4) is noninferior to quadrivalent inactivated influenza vaccine (IIV4) for frequency of asthma exacerbations.
Researchers compared the incidence of intra-familial influenza transmission after treatment of the first family member with baloxavir marboxil vs oseltamivir.
Researchers examined the safety and immunogenicity of administering a high-dose quadrivalent influenza vaccine and a third dose of mRNA-1273 vaccine booster concomitantly.